GENB — Generate Biomedicines Balance Sheet
0.000.00%
Last trade - 00:00- $1.43bn
- $1.44bn
- $31.89m
Annual balance sheet for Generate Biomedicines, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2024 December 31st | 2025 December 31st | |
|---|---|---|
| Period Length: | — | — |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Cash and Equivalents | ||
| Short Term Investments | ||
| Cash and Short Term Investments | 394 | 221 |
| Net Total Accounts Receivable | ||
| Net Total Receivables | 0.308 | 0 |
| Prepaid Expenses | ||
| Total Other Current Assets | ||
| Total Current Assets | 407 | 234 |
| Gross Property, Plant And Equipment | ||
| Accumulated Depreciation | ||
| Net Property, Plant And Equipment | 101 | 89 |
| Other Long Term Assets | ||
| Total Assets | 518 | 330 |
| Accounts Payable | ||
| Accrued Expenses | ||
| Notes Payable / Short Term Debt | ||
| Current Portion of Long Term Debt / Capital Leases | ||
| Total Other Current Liabilities | ||
| Total Current Liabilities | 86.6 | 82.2 |
| Capital Lease Obligations | ||
| Total Long Term Debt | ||
| Total Debt | ||
| Minority Interest | ||
| Total Other Liabilities | ||
| Total Liabilities | 163 | 134 |
| Non Redeemable Preferred Stock | ||
| Common Stock | ||
| Additional Paid In Capital | ||
| Retained Earnings (Accumulated Deficit) | ||
| Unrealized Gain / Loss | ||
| Total Equity | 355 | 196 |
| Total Liabilities & Shareholders' Equity | 518 | 330 |
| Total Common Shares Outstanding |